Diabetes mellitus and hyperhomocysteinemia.

Area of Science:

• Cardiovascular Research
• Metabolic Disorders
• Clinical Nutrition

Background:

• Patients with diabetes mellitus (DM) have increased cardiovascular disease (CVD) risk.
• Hyperhomocysteinemia, a condition of elevated homocysteine, is a potential contributor to atherothrombosis in diabetic individuals.
• While plasma homocysteine levels are typically normal in diabetes, variations can occur due to factors like renal function and folate status.

Purpose of the Study:

• To investigate the association between plasma homocysteine levels and cardiovascular risk factors in patients with diabetes mellitus.
• To explore the relationship between hyperhomocysteinemia and microvascular and macrovascular complications in type 1 and type 2 diabetes.
• To determine if homocysteine levels predict adverse outcomes, including mortality, in diabetic populations.

Main Methods:

• Review of existing literature on plasma homocysteine levels in diabetic patients.
• Analysis of studies correlating homocysteine concentrations with microalbuminuria, retinopathy, and macrovascular disease.
• Examination of data comparing the association of hyperhomocysteinemia with vascular risk in diabetic versus non-diabetic subjects.

Main Results:

• Hyperhomocysteinemia is linked to microalbuminuria and retinopathy in both type 1 and type 2 diabetes.
• In type 2 diabetes, higher plasma homocysteine concentrations correlate with macrovascular disease and mortality, with a stronger association than in non-diabetics.
• Insulin resistance was not found to be a significant determinant of plasma homocysteine levels.

Conclusions:

• Hyperhomocysteinemia may synergistically increase vascular risk in patients with diabetes.
• Diabetic patients with hyperhomocysteinemia are candidates for screening and potential folic acid treatment to mitigate vascular complications.
• Further clinical trials are needed to confirm the efficacy of homocysteine-lowering therapies in this population.